
- /
- Supported exchanges
- / US
- / BCAB.NASDAQ
Bioatla Inc (BCAB NASDAQ) stock market data APIs
Bioatla Inc Financial Data Overview
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Bioatla Inc data using free add-ons & libraries
Get Bioatla Inc Fundamental Data
Bioatla Inc Fundamental data includes:
- Net Revenue: 11 000 K
- EBITDA: -85 170 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-24
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Bioatla Inc News

BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings
SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody t...


BioAtla, Inc. (BCAB): Among Michael Burry’s Top 10 Stock Picks Heading Into 2025
We recently compiled a list of the Michael Burry's Top 10 Stock Picks Heading into 2025.In this article, we are going to take a look at where BioAtla, Inc. (NASDAQ:BCAB) stands against Michael Burry's...

Michael Burry of ‘The Big Short' increases Alibaba stake, halves stock portfolio
Investing.com - Michael Burry, the hedge fund manager famous for his 2008 bet against the US housing market depicted in "The Big Short," has further increased his stake in Alibaba Group Holdings Ltd A...

Co-Founder of BioAtla Jay Short Buys 2.3% More Shares
Investors who take an interest in BioAtla, Inc. (NASDAQ:BCAB) should definitely note that the Co-Founder, Jay Short, recently paid US$2.14 per share to buy US$107k worth of the stock. While that's a v...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.